---

Antihistamine Drugs: Basics to Clinical

---

1. Histamine - The Foundation

Synthesis and Storage

• Histamine is formed by decarboxylation of L-histidine (enzyme: histidine decarboxylase)
• Stored in mast cell granules and basophil granules bound to heparin proteoglycans
• Also found in enterochromaffin-like (ECL) cells of the gastric mucosa and histaminergic neurons of the CNS (tuberoammillary nucleus of the posterior hypothalamus)

Histamine Receptors

Pathophysiological Actions of Histamine

1. Initial red spot - direct H1-mediated vasodilation (NO production)
2. Flare - axonal reflex-mediated indirect vasodilation
3. Wheal - ↑capillary permeability → edema

---

2. Classification of Antihistamines

Important pharmacological note: H1 antagonists are technically inverse agonists - they reduce constitutive receptor activity AND compete with histamine. They don't just block; they reverse baseline receptor tone.

H1 Antihistamines (Anti-allergic)

Generation 1 vs Generation 2 - Key Comparison

---

3. First-Generation H1 Antihistamines (by Chemical Class)

A. Ethanolamines - Prototype: Diphenhydramine (Benadryl)

• Strong anticholinergic + sedative effects
• ~50% of patients get significant somnolence
• Low GI side effects
• Uses: Allergic reactions, motion sickness, insomnia, anaphylaxis (adjunct), Parkinsonism (anti-muscarinic benefit)
• Other members: Clemastine, dimenhydrinate (for motion sickness)

B. Ethylenediamines - Prototype: Pyrilamine (Mepyramine)

• Among the most H1-selective of the first-generation drugs
• Relatively weak CNS effects, but some sedation
• GI side effects are common
• Other members: Tripelennamine

C. Alkylamines - Prototype: Chlorpheniramine (Chlor-Trimeton)

• Among the most potent H1 antagonists
• Less sedation than ethanolamines - better for daytime use
• More CNS stimulation side effects than other groups
• Uses: Allergic rhinitis, urticaria, common cold formulations
• Other members: Brompheniramine, dexchlorpheniramine (active enantiomer)

D. Piperazines (First-Generation) - Prototype: Hydroxyzine (Atarax/Vistaril)

• Long-acting compound
• Prominent CNS depression - contributes to antipruritic action
• Uses: Skin allergies (urticaria, atopic dermatitis), anxiety, pre-operative sedation
• Cyclizine and meclizine - primarily for motion sickness

E. Phenothiazines - Prototype: Promethazine (Phenergan)

• Significant sedative + strong anticholinergic
• Also a dopamine (D2) receptor blocker
• Uses: Antiemetic (primary use), pre-operative sedation, motion sickness, adjunct to opioid analgesia
• Warning: Not recommended in children under 2 years (risk of fatal respiratory depression)

F. Piperidines (First-Generation) - Prototype: Cyproheptadine (Periactin)

• Uniquely has both H1 antihistamine AND 5-HT2A antiserotonin activity
• Causes drowsiness + significant anticholinergic effects
• Stimulates appetite (used clinically for appetite stimulation, anorexia)
• Uses: Urticaria, pruritus, serotonin syndrome (5-HT2A antagonism), appetite stimulation, migraine prophylaxis

---

4. Second-Generation H1 Antihistamines

A. Piperidines (Second-Generation) - Loratadine, Fexofenadine, Desloratadine

• Prodrug - metabolized to active desloratadine
• Non-sedating, no anticholinergic effects
• Poor CNS penetration (P-gp substrate)
• Uses: Allergic rhinitis, chronic urticaria

• Active metabolite of terfenadine (which was withdrawn for torsade de pointes risk)
• Lacks the cardiac toxicity of terfenadine
• Does not penetrate CNS
• Uses: Seasonal allergic rhinitis, urticaria

• Active metabolite of loratadine; slightly more potent
• Mast cell-stabilizing + anti-inflammatory properties
• Uses: Allergic rhinitis, urticaria

Historical note: Terfenadine and astemizole (early 2nd-gen) were withdrawn from the market because they blocked cardiac hERG K⁺ channels → prolonged QT → torsade de pointes. This is especially dangerous when combined with CYP3A4 inhibitors (azole antifungals, macrolide antibiotics) that increase their blood levels.

B. Piperazines (Second-Generation) - Cetirizine, Levocetirizine

• Metabolite of hydroxyzine
• Minimal anticholinergic effects, low CNS penetration
• Slightly more sedating than other 2nd-gen agents (still much less than 1st gen)
• Additional mast cell-stabilizing and anti-inflammatory properties
• Uses: Allergic rhinitis, chronic urticaria, atopic dermatitis

• Active R-enantiomer of cetirizine
• ~2x more potent; used at half the dose
• Less sedation than racemic cetirizine
• Mast cell-stabilizing properties

C. Alkylamine (Second-Generation) - Acrivastine

• Derivative of triprolidine (first-gen)
• Slightly more sedating than other 2nd-gen agents

D. Dibenzoxepine Tricyclic (Topical) - Olopatadine (Patanol, Pataday)

• Topical H1 antagonist + mast cell stabilizer + anti-inflammatory
• Available as eye drops (allergic conjunctivitis) and nasal spray (allergic rhinitis)
• Minimal systemic absorption - essentially no systemic side effects

---

5. H2 Antihistamines (Antisecretory)

---

6. H3 and H4 Receptor Antagonists (Emerging)

• Pitolisant (Wakix) - FDA approved for narcolepsy (increases histamine release in CNS → promotes wakefulness)
• Investigational in ADHD, Alzheimer's, obesity

• None FDA-approved yet
• Promising for allergic rhinitis, asthma, atopic dermatitis, pruritus, rheumatoid arthritis

---

7. Pharmacokinetics Summary

---

8. Clinical Uses (Consolidated)

---

9. Adverse Effects

First-Generation

• CNS: Sedation, impaired cognition, paradoxical excitation (especially in children)
• Anticholinergic: Dry mouth, urinary retention, blurred vision, constipation, tachycardia
• GI: Nausea, epigastric distress (ethylenediamines)
• CV: QT prolongation risk (terfenadine, astemizole - now withdrawn)

Second-Generation

• Minimal sedation (cetirizine slightly more than others)
• Minimal anticholinergic
• No significant QT prolongation risk at therapeutic doses
• Headache, fatigue, dry mouth (mild)

H2 Blockers

• Cimetidine: Gynecomastia, impotence, confusion (elderly), many drug interactions (CYP1A2, 2C9, 2D6, 3A4 inhibition)
• Generally well tolerated as a class

---

10. Important Drug Interactions

• Cimetidine inhibits multiple CYP enzymes - interacts with warfarin, phenytoin, theophylline, tricyclic antidepressants
• 1st-gen antihistamines + CNS depressants (alcohol, benzodiazepines, opioids) - additive sedation
• CYP3A4 inhibitors (ketoconazole, erythromycin) historically raised terfenadine/astemizole levels → torsade de pointes (reason for withdrawal)
• Anticholinergic additive effects with other antimuscarinic drugs

---

11. Special Populations

• Chlorpheniramine and diphenhydramine - traditionally considered relatively safe (category B)
• Loratadine and cetirizine - preferred 2nd-gen options in pregnancy

• Avoid 1st-gen antihistamines (Beers Criteria) - risk of confusion, falls, urinary retention, constipation
• Use 2nd-gen at lowest effective dose

• Promethazine contraindicated <2 years (fatal respiratory depression risk)
• Cetirizine and loratadine safe and approved for children ≥2 years

• Fexofenadine, cetirizine, levocetirizine - dose reduction needed (renal excretion)

---

Quick Memory Mnemonic

• C = Chlorpheniramine (alkylamine) - most potent, least sedating 1st-gen
• A = Anti-muscarinic (diphenhydramine) - most sedating
• P = Promethazine (phenothiazine) - antiemetic
• F = Fexofenadine - no sedation, no interaction
• L = Loratadine - once daily, non-sedating
• D = Desloratadine/cetirizine - 2nd gen standard

---

---

Pancreatitis: Basics to Clinical Management

---

Part 1: Anatomy Basics

• The neck overlies L1-L2 vertebrae - blunt trauma here can compress the pancreas against the spine, causing duct injury
• The tail is nestled in the splenic hilum - at risk during splenectomy or left colectomy
• The main pancreatic duct (duct of Wirsung) joins the common bile duct at the ampulla of Vater to drain into the duodenum at the major papilla
• The duct of Santorini (accessory duct) drains through the minor papilla
• Pancreas divisum (failure of ventral and dorsal buds to fuse during embryogenesis) is the most common congenital anomaly - a risk factor for pancreatitis due to relative outflow obstruction

Exocrine Function (Relevant to Pancreatitis)

• Digestive enzymes (proteases, lipases, amylase) - secreted as inactive zymogens to prevent autodigestion
• Bicarbonate-rich fluid - to neutralize gastric acid in the duodenum
• Stimulated by secretin (HCO₃ secretion) and CCK (enzyme secretion)

1. Enzymes synthesized as inactive zymogens (trypsinogen, chymotrypsinogen, proelastase, prophospholipase)
2. Zymogens stored in separate granules from lysosomal enzymes
3. SPINK1 (serine protease inhibitor Kazal type 1) - a trypsin inhibitor inside acinar cells
4. Trypsin self-inactivates by cleaving itself (negative feedback)

---

Part 2: Acute Pancreatitis

Definition

• Annual incidence: 33-74 per 100,000 globally
• Overall mortality: ~5% (rising with severity)
• 80% of cases are mild and self-limiting; 20% develop severe disease

---

Etiology - "I GET SMASHED" Mnemonic

Gallstones + Alcohol = ~80% of all acute pancreatitis cases

---

Pathophysiology

Three Pathways of Initiation:

• Gallstone impaction → ↑intraductal pressure → enzyme-rich interstitial fluid accumulation
• Lipase (secreted in active form) → local fat necrosis
• Injured tissue releases cytokines → local inflammation + interstitial edema
• Edema compromises blood flow → ischemia → more acinar cell injury

• Alcohol: transiently ↑exocrine secretion + contracts sphincter of Oddi → obstructs outflow; also direct toxic effect on acinar cells; promotes protein plug formation in ducts
• Large TG-rich chylomicrons retard capillary flow → ischemic acinar cell injury → lipase release → free fatty acid toxicity
• Direct viral infection of acinar cells (mumps, coxsackievirus)

• Normally, digestive enzymes (zymogen granules) and lysosomal hydrolases travel in separate pathways
• In metabolic injury/alcohol: proenzymes co-packaged with lysosomal enzymes (cathepsin B) → intracellular trypsinogen activation → lysosomal rupture → enzyme release

Once Trypsin is Activated (the "Master Activator"):

• Activates all other zymogens: chymotrypsin, elastase, phospholipase A2, kallikrein
• Converts prekallikrein → kinin system activation (vasodilation, ↑permeability)
• Activates factor XII (Hageman) → clotting + complement cascade
• Elastase → vessel wall damage → hemorrhage
• Lipase/phospholipase → fat necrosis
• Released enzymes → systemic SIRS → ARDS, DIC, renal failure, shock

---

Morphology (Gross and Microscopic - Robbins)

• Interstitial edema
• Focal areas of fat necrosis (yellow-white chalky deposits - calcium soaps from saponification)
• Preserved pancreatic architecture

• Damage to acinar cells, ductal cells, islets of Langerhans, and blood vessels
• Macroscopic: Red-black hemorrhagic areas + yellow-white chalky fat necrosis
• Fat necrosis can extend to omentum, bowel mesentery, even subcutaneous fat
• Peritoneal cavity: serous brown-tinged fluid with fat globules

• Interstitial edema
• Neutrophilic infiltration
• Fat necrosis with calcium soap deposits (basophilic granular material)
• Acinar cell necrosis (ghost cells with pyknotic nuclei)
• Vascular injury with hemorrhage

---

Clinical Features

• Abdominal pain - cardinal feature; sudden onset, severe, epigastric/periumbilical, radiates to the back ("bores through to the back")
• Pain is constant and intense - differs from biliary colic (colicky)
• Nausea and vomiting - does not relieve pain (unlike bowel obstruction)
• Low-grade fever

• Epigastric tenderness ± guarding and rigidity
• Reduced or absent bowel sounds (paralytic ileus)
• Cullen's sign - periumbilical bruising (retroperitoneal hemorrhage tracking to umbilicus)
• Grey Turner's sign - flank bruising (retroperitoneal hemorrhage tracking to flanks)
• Fox's sign - bruising at inguinal ligament
• Jaundice (if gallstone blocks CBD)
• In severe cases: peripheral vascular collapse (shock)

---

Investigations

• Serum amylase - rises within 6-12 hours, peaks at 24 hours, returns to normal in 3-5 days. Sensitivity ~80%, specificity ~70%. Can be normal in severe necrotic pancreatitis (no remaining acinar tissue)
• Serum lipase - more sensitive and specific than amylase; rises later but stays elevated longer (7-14 days); preferred diagnostic marker

Diagnosis requires serum lipase or amylase >3x upper limit of normal

• CBC: leukocytosis
• CMP: elevated BUN/creatinine (hypovolemia), ↑glucose
• LFTs: elevated AST/ALT/bilirubin/ALP suggest gallstone etiology
• Serum calcium: ↓(saponification of fat consumes calcium) - hypocalcemia = poor prognosis
• Serum triglycerides
• ABG in severe cases (for ARDS monitoring)
• CRP >150 mg/L at 48 hours = marker of severe disease

---

Severity Assessment and Scoring Systems

1. Revised Atlanta Classification (2012)

2. Ranson's Criteria

1. Age >55 years
2. WBC >16,000/mm³
3. Blood glucose >200 mg/dL
4. Serum LDH >350 IU/L
5. AST >250 IU/L

1. Hematocrit drop >10%
2. BUN rise >5 mg/dL
3. Serum Ca²⁺ <8 mg/dL
4. PaO₂ <60 mmHg
5. Base deficit >4 mEq/L
6. Fluid sequestration >6 L

• 0-2: mild (mortality <1%)
• 3-4: ~16% mortality
• 5-6: ~40% mortality

• 6: ~100% mortality

3. APACHE II Score

• Score >8 at 48 hours = severe acute pancreatitis
• Can be calculated daily; useful for ICU monitoring

4. CT Severity Index (Balthazar/CTSI)

• A: Normal pancreas (0)
• B: Pancreatic enlargement (1)
• C: Peripancreatic inflammation (2)
• D: Single extrapancreatic fluid collection (3)
• E: Two or more fluid collections (4)

• No necrosis (0)
• <30% (2)
• 30-50% (4)

• 50% (6)

5. BISAP Score (Bedside Index of Severity in Acute Pancreatitis)

• B - BUN >25 mg/dL
• I - Impaired mental status
• S - SIRS (≥2 of 4 criteria)
• A - Age >60 years
• P - Pleural effusion on imaging

---

Complications

Local Complications:

Systemic Complications:

• ARDS - most common pulmonary complication (activated phospholipase A2 damages surfactant)
• Acute kidney injury - hypovolemia + systemic inflammation
• DIC - kinin + clotting cascade activation by trypsin
• Shock - hypovolemia from third-spacing, vasodilation
• Hyperglycemia - islet cell destruction
• Hypocalcemia - saponification (Ca²⁺ consumed by fat necrosis)
• Ileus / bowel obstruction

---

Part 3: Management of Acute Pancreatitis

General Principles (Conservative)

• Restore and maintain circulating blood volume
• Lactated Ringer's solution preferred over normal saline (reduces SIRS response in studies)
• Moderate resuscitation: restore normal BP, HR, and urine output (target UO >0.5 mL/kg/hr)
• Avoid over-resuscitation in elderly, cardiac/renal disease patients
• Monitor response with clinical parameters + BUN trends

• IV opioid analgesia (morphine, hydromorphone, or fentanyl)
• Historical concern about morphine (sphincter of Oddi spasm) is largely dismissed clinically
• Epidural analgesia for severe pancreatitis (reduces ileus, improves splanchnic flow)

• Traditional: NPO until pain resolves
• Current evidence: early enteral nutrition is superior to parenteral nutrition

• Mild pancreatitis: Oral feeding can be started as soon as tolerated (even low-fat solids)
• Severe pancreatitis: Early enteral feeding via nasojejunal (NJ) or nasogastric (NG) tube within 24-48 hours
• Enteral nutrition preferred over TPN - maintains gut barrier integrity, reduces bacterial translocation, reduces infectious complications
• TPN only if enteral route not feasible

• ICU admission for severe acute pancreatitis
• Continuous monitoring: vitals, urine output, oxygen saturation
• Serial labs: CBC, CMP, Ca²⁺, CRP, LFTs
• Daily reassessment of organ function

• NOT routine in acute pancreatitis (multiple RCTs failed to show benefit)
• Antibiotics indicated ONLY for:
  • Confirmed infected pancreatic necrosis (positive cultures or CT showing gas in necrosis)
  • Concurrent cholangitis
  • Other proven infections (pneumonia, UTI, bacteremia)
• Imipenem or meropenem - best pancreatic tissue penetration if needed

• Gallstone pancreatitis with cholangitis / persistent CBD obstruction: Urgent ERCP (within 24-72 hours)
• Gallstone pancreatitis (mild, resolving): Elective cholecystectomy during same admission or within 2-4 weeks (before it recurs - 30-60% recurrence without definitive treatment)
• Alcohol-related: Counseling + cessation
• Hypertriglyceridemia: Insulin drip (activates lipoprotein lipase) ± plasmapheresis for TG >1000 mg/dL
• Hypercalcemia: Treat underlying cause (hyperparathyroidism)
• Drug-induced: Stop the offending drug

---

Management of Complications

• Small, asymptomatic: observation - majority resolve spontaneously
• Symptomatic, enlarging, infected, or not resolving after 6 weeks: drainage
• Endoscopic cyst-gastrostomy or cyst-duodenostomy (preferred when pseudocyst is adherent to stomach/duodenum)
• Percutaneous CT-guided drainage (if infected or not accessible endoscopically)
• Surgical: cystogastrostomy, Roux-en-Y cystojejunostomy (less common now)

• Antibiotics alone insufficient for established infected necrosis
• Step-up approach (current standard):
  1. Antibiotics (carbapenem)
  2. If no improvement: percutaneous/endoscopic drainage
  3. If still failing: minimally invasive necrosectomy (video-assisted retroperitoneal debridement - VARD, or endoscopic transgastric necrosectomy)
  4. Open surgical necrosectomy as last resort (highest morbidity)
• Timing: defer intervention until necrosis is "walled off" (>4 weeks if possible) - better-defined margins, lower bleeding risk

---

Part 4: Chronic Pancreatitis

Definition

Etiology (TIGAR-O Classification)

• T - Toxic-metabolic: alcohol (most common in Western countries), tobacco, hypercalcemia, hyperlipidemia, chronic renal failure
• I - Idiopathic (15-25%)
• G - Genetic: PRSS1 (hereditary pancreatitis), SPINK1, CFTR mutations
• A - Autoimmune: IgG4-related, isolated autoimmune CP
• R - Recurrent and severe acute pancreatitis
• O - Obstructive: pancreas divisum, ductal strictures, tumors, trauma

Genetics of Hereditary Pancreatitis

• PRSS1 mutations (cationic trypsinogen gene, chromosome 7q35): R122H and N291 mutations = ~2/3 of hereditary cases; gain-of-function → prevents trypsin self-inactivation → persistent trypsin activity
• SPINK1 mutations: loss-of-function → reduced trypsin inhibition → uncontrolled activation
• CFTR mutations: defective bicarbonate/fluid secretion → viscous secretions → duct plugging
• Pattern: autosomal dominant with 80% penetrance; presents in childhood/adolescence
• Risk of pancreatic cancer: 40% lifetime risk in PRSS1 hereditary pancreatitis

Pathology (Chronic)

• Extensive fibrosis replacing acinar tissue
• Acinar atrophy - exocrine insufficiency
• Islets of Langerhans preserved initially, then destroyed in late stages → Type 3c diabetes (pancreatogenic)
• Ductal changes: dilated ducts, intraductal calcifications (protein plugs → calcify)
• Chronic inflammatory cell infiltrate (lymphocytes, plasma cells)

Clinical Features

• Chronic abdominal pain - most common symptom; epigastric, radiates to back; exacerbated by eating or alcohol
• Episodic acute attacks (acute-on-chronic)
• Exocrine insufficiency: steatorrhea (fatty, foul-smelling, floating stools), weight loss, malabsorption of fat-soluble vitamins (A, D, E, K)
• Vitamin D deficiency → osteopenia/osteoporosis
• Endocrine insufficiency: diabetes mellitus (Type 3c) - brittle, difficult to manage
• Jaundice (CBD compression by fibrosis or pseudocyst)
• Precipitated by: excess alcohol, overeating, opiates (↑sphincter of Oddi tone)

Diagnosis

• Clinical suspicion + history
• Elevated serum amylase/lipase (may be normal in burned-out disease)
• CT/MRI: pancreatic calcifications (pathognomonic), ductal dilation, atrophy
• MRCP: duct irregularity ("chain of lakes" appearance in ductal dilation)
• Fecal elastase-1: low (<200 μg/g) indicates exocrine insufficiency
• Secretin stimulation test: gold standard for exocrine function

Management of Chronic Pancreatitis

• Absolute alcohol abstinence
• Smoking cessation
• Low-fat diet

• WHO analgesic ladder: NSAIDs → weak opioids → strong opioids
• Pancreatic enzyme supplementation - reduces CCK-mediated pancreatic stimulation → pain relief
• Celiac plexus block (EUS-guided or percutaneous) - temporary pain relief
• Tricyclic antidepressants, pregabalin - centrally-mediated pain modulation

• For exocrine insufficiency: high-dose pancreatic enzyme supplements (pancrelipase) with every meal
• Fat-soluble vitamin supplementation (A, D, E, K)

• Pancreatic duct stenting for dominant strictures
• Stone removal (extracorporeal shock wave lithotripsy - ESWL first, then endoscopy) for ductal calculi
• Sphincterotomy

• Indicated for: intractable pain, duodenal/biliary obstruction, suspicion of malignancy, failed endoscopic therapy
• Drainage procedures (for dilated duct >6mm):
  • Puestow procedure (lateral pancreaticojejunostomy): duct opened longitudinally and anastomosed to Roux-en-Y jejunum
  • Frey procedure: combines ductal drainage with partial head coring (addresses the "pacemaker" of pain in the head)
• Resection procedures (for non-dilated duct or head-predominant disease):
  • Whipple (pancreaticoduodenectomy): head/neck resection; high morbidity
  • Beger procedure: duodenum-preserving pancreatic head resection
  • Distal pancreatectomy: for body/tail disease
• Total pancreatectomy with islet autotransplantation (TPIAT): for refractory pain, especially hereditary pancreatitis in young patients

• Type 3c diabetes (pancreatogenic) - different from Type 1/Type 2
• Brittle: prone to hypoglycemia (also lost glucagon from alpha cells)
• Insulin therapy usually required in advanced disease
• Avoid sulfonylureas (worsen hypoglycemia risk)

---

Summary Comparison Table

---

Quick Clinical Pearls

1. Grey Turner + Cullen signs = retroperitoneal hemorrhage = severe necrotizing pancreatitis
2. Hypocalcemia in acute pancreatitis = fat saponification = bad prognostic sign
3. Lipase > Amylase diagnostically - more specific and stays elevated longer
4. ERCP in gallstone pancreatitis = only if concurrent cholangitis or CBD obstruction persists
5. Enteral > parenteral nutrition in severe acute pancreatitis
6. Step-up approach for infected necrosis - avoid early open surgery
7. "Walled-off necrosis" - wait >4 weeks before draining
8. Amylase can be normal in chronic pancreatitis (insufficient acinar tissue left)
9. PRSS1 gain-of-function = hereditary pancreatitis = 40% lifetime pancreatic cancer risk
10. Cholecystectomy during same admission in mild biliary pancreatitis to prevent recurrence

---

---

Pancreatitis: Basics to Clinical Management

---

Part 1: Anatomy Basics (The Foundation)

• The neck lies over L1-L2 - blunt trauma compresses it against the spine, causing ductal injury
• The tail sits in the splenic hilum - vulnerable during splenectomy or left colectomy
• The duct of Wirsung (main duct) + common bile duct join at the ampulla of Vater, draining into the duodenum
• Pancreas divisum (failed ventral-dorsal fusion) is the most common congenital anomaly and a risk factor for pancreatitis

Why Doesn't the Pancreas Digest Itself Normally?

1. Enzymes made as inactive zymogens (trypsinogen, chymotrypsinogen, proelastase)
2. Zymogens stored in separate granules from lysosomal hydrolases
3. SPINK1 - a trypsin inhibitor inside acinar cells
4. Trypsin self-inactivates by cleaving itself (negative feedback loop)

---

Part 2: Acute Pancreatitis

Definition

• Incidence: 33-74 per 100,000 globally
• Overall mortality: ~5%; rising to 30-50% in severe disease
• 80% mild and self-limiting; 20% develop severe disease

---

Etiology - "I GET SMASHED"

Gallstones + Alcohol together account for ~80% of all acute pancreatitis cases.

---

Pathophysiology

Three Initiating Pathways:

• ↑intraductal pressure → enzyme-rich interstitial accumulation
• Lipase (secreted already active) → immediate fat necrosis
• Injured tissue releases cytokines → edema → ischemia → more injury

• Alcohol: ↑exocrine secretion + sphincter of Oddi contraction → outflow obstruction + direct toxicity; promotes protein plug formation in ducts
• Hypertriglyceridemia: chylomicrons retard capillary flow → ischemia → lipase release → toxic free fatty acids
• Direct viral acinar cell infection

• Digestive proenzymes co-packaged with lysosomal hydrolases (cathepsin B)
• Intracellular trypsinogen activation → lysosomal rupture → cascading enzyme release

The Trypsin Cascade - "Master Activator":

• Other zymogens: chymotrypsin, elastase, phospholipase A2
• Kinin system (via kallikrein) → vasodilation + ↑permeability
• Clotting cascade (via factor XII/Hageman) → DIC
• Complement system → systemic SIRS
• Elastase → vessel wall destruction → hemorrhage
• Phospholipase A2 → damages surfactant → ARDS
• Lipase → fat necrosis → calcium soap precipitation → hypocalcemia

---

Morphology

• Interstitial edema
• Focal fat necrosis (yellow-white chalky deposits = calcium soaps)
• Preserved architecture, no vascular injury

• Damage extends to acini, ducts, islets, and blood vessels
• Peritoneal fluid: serous, brown-tinged, with fat globules
• Fat necrosis can extend to omentum, mesentery, even subcutaneous fat
• Histology: neutrophilic infiltration, acinar cell necrosis, vascular injury, hemorrhage

---

Clinical Presentation

• Epigastric pain - sudden, severe, constant, bores through to the back (mid-thoracic)
• Nausea and vomiting (does not relieve pain - distinguishes from bowel obstruction)
• Low-grade fever

• Epigastric tenderness ± guarding, rigidity
• Absent or reduced bowel sounds (paralytic ileus)
• Cullen's sign - periumbilical bruising (retroperitoneal hemorrhage tracking forward)
• Grey Turner's sign - flank bruising (retroperitoneal hemorrhage tracking laterally)
• Jaundice if gallstone obstructs CBD
• Shock in severe cases (hypovolemia + vasodilation)

---

Investigations

• Leukocytosis, ↑glucose, ↑BUN/Cr (hypovolemia)
• ↑ALT >3x = strongly suggests gallstone etiology (>95% PPV in right clinical context)
• ↓Ca²⁺ = saponification = severe disease / poor prognosis
• ↑TG if hypertriglyceridemia is cause
• CRP >150 mg/L at 48 hours = marker of severity

---

Severity Scoring

Revised Atlanta Classification (2012) - Current Standard:

Ranson's Criteria (11 factors):

• G - Glucose >200 mg/dL
• A - Age >55
• L - LDH >350 IU/L
• B - (W)BC >16,000
• U - (as)T >250 IU/L (= AST)

• H - Hematocrit drop >10%
• O - (BUN rise >5 = "Oh no, kidneys")
• B - Base deficit >4
• B - (Ca²⁺) <8 mg/dL
• S - Sequestration of fluid >6 L; PaO₂ <60 mmHg

BISAP Score (≥3 = severe):

• BUN >25, Impaired mental status, SIRS, Age >60, Pleural effusion

CT Severity Index (Balthazar + Necrosis score):

• Score >6 = severe (mortality 17%, morbidity 92%)

---

Local Complications (Atlanta 2012 Definitions):

Systemic Complications:

• ARDS - phospholipase A2 damages alveolar surfactant
• AKI - hypovolemia + inflammation
• DIC - trypsin activates factor XII + clotting cascade
• Shock - third spacing of fluid, systemic vasodilation
• Hyperglycemia - islet cell destruction
• Hypocalcemia - fat saponification
• Ileus, pancreatic ascites, left-sided pleural effusion

---

Part 3: Treatment and Management of Acute Pancreatitis

Step 1: Fluid Resuscitation (MOST IMPORTANT early intervention)

• Lactated Ringer's solution preferred over normal saline (reduces SIRS in studies)
• Goal: restore normal BP, heart rate, urine output >0.5 mL/kg/hr
• Moderate resuscitation (avoid excessive fluid in elderly/cardiac/renal patients)
• Monitor with BUN trends (rising BUN = inadequate resuscitation)

Step 2: Analgesia

• IV opioids (fentanyl, hydromorphone, morphine)
• Historical avoidance of morphine (sphincter of Oddi concern) is no longer clinically relevant
• Epidural analgesia in severe cases

Step 3: Nutrition

• Mild pancreatitis: Early oral feeding as soon as tolerated (low-fat soft diet)
• Severe pancreatitis: Early enteral nutrition within 24-48 hours (nasogastric or nasojejunal tube)
• Enteral > TPN: maintains gut barrier, reduces bacterial translocation, fewer infectious complications, lower cost
• TPN only if enteral route is impossible

Step 4: Antibiotics

• NOT routine - multiple RCTs showed no benefit for prophylactic antibiotics
• Use ONLY for:
  • Confirmed infected pancreatic necrosis (gas on CT or positive cultures)
  • Associated cholangitis
  • Other proven infections
• Agent: imipenem/meropenem (best pancreatic penetration)

Step 5: Treat the Cause

Step 6: Monitoring (ICU for Severe Cases)

• Continuous monitoring of vitals, urine output, SpO₂
• Serial labs: BUN, Cr, Ca²⁺, CBC, CRP, LFTs
• Daily organ failure assessment
• CECT at 48-72 hours if clinical deterioration

Management of Infected Necrosis - Step-Up Approach (Current Standard)

1. Antibiotics (carbapenem) + NPO + supportive care
2. If no improvement at 72-96 hours: percutaneous CT-guided drainage or endoscopic transluminal drainage (transgastric)
3. If still failing: minimally invasive necrosectomy (video-assisted retroperitoneal debridement - VARD, or endoscopic necrosectomy)
4. Open surgical necrosectomy - last resort; highest morbidity

Key principle: Wait until necrosis is walled off (>4 weeks) before intervention if clinically possible - margins are better defined, bleeding risk is lower.

---

Part 4: Chronic Pancreatitis

Definition

Etiology - TIGAR-O

• Toxic-metabolic: alcohol, tobacco, hypercalcemia, hypertriglyceridemia, chronic renal failure
• Idiopathic: 15-25%
• Genetic: PRSS1, SPINK1, CFTR mutations
• Autoimmune: IgG4-related
• Recurrent severe acute pancreatitis
• Obstructive: pancreas divisum, strictures, tumors

Genetics of Hereditary Pancreatitis

• PRSS1 gene (cationic trypsinogen, chromosome 7q35): R122H and N291 mutations = gain-of-function → trypsin cannot self-inactivate → persistent autodigestion
• SPINK1 mutations: loss-of-function trypsin inhibitor → uncontrolled trypsin activity
• CFTR mutations: defective bicarbonate/fluid secretion → viscous secretions → duct plugging
• Autosomal dominant, 80% penetrance; presents in childhood
• Lifetime pancreatic cancer risk: 40% in PRSS1 hereditary pancreatitis

Pathology

• Extensive fibrosis replacing acinar tissue
• Acinar atrophy → exocrine insufficiency
• Islets preserved initially, then destroyed → Type 3c diabetes
• Ductal calcifications (protein plugs calcify) - pathognomonic on imaging
• Dilated ducts ("chain of lakes" on MRCP)

Clinical Features

• Chronic epigastric pain radiating to back; worse with eating + alcohol; improves leaning forward
• Steatorrhea - foul-smelling, floating, fatty stools; requires >90% exocrine destruction to manifest
• Weight loss and malabsorption
• Fat-soluble vitamin deficiency (A, D, E, K) → osteoporosis (Vitamin D), coagulopathy (Vitamin K)
• Type 3c (pancreatogenic) diabetes - brittle, prone to hypoglycemia (lost glucagon from alpha cells too)
• Jaundice (CBD stricture from fibrosis)
• Episodes of acute-on-chronic exacerbations

Investigations

• Amylase/lipase may be normal in burned-out disease (insufficient acinar tissue)
• CT: pancreatic calcifications, ductal dilation, atrophy
• MRCP: ductal irregularity, strictures, "chain of lakes"
• Fecal elastase-1 <200 μg/g = exocrine insufficiency
• Secretin stimulation test = gold standard for exocrine function
• Glucose tolerance test for diabetes

Treatment of Chronic Pancreatitis

• Absolute alcohol abstinence
• Smoking cessation
• Low-fat diet (5-6 small meals/day)

• WHO ladder: paracetamol/NSAIDs → tramadol → strong opioids
• Pancreatic enzyme supplements - reduce CCK-driven pancreatic stimulation → pain relief
• Pregabalin, tricyclic antidepressants - centrally-mediated pain
• Celiac plexus block (EUS-guided) - temporary relief

• Pancrelipase (high lipase content) with every meal and snacks
• Fat-soluble vitamins supplementation (A, D, E, K)
• Goal: eliminate steatorrhea, restore normal nutrition

• Insulin (usually required in advanced disease)
• Avoid sulfonylureas - risk of severe hypoglycemia
• Monitor carefully (brittle hypoglycemia risk)

• Ductal stenting for dominant strictures
• ESWL (extracorporeal shock wave lithotripsy) for calculi → then endoscopic stone removal
• Pancreatic sphincterotomy

• Intractable pain unresponsive to medical/endoscopic therapy
• Duodenal or biliary obstruction
• Suspicion of malignancy
• Pancreatic fistula

---

Summary Comparison

---

10 High-Yield Clinical Pearls

1. Lipase > Amylase as the diagnostic test - more specific, stays elevated longer
2. ALT >3x = gallstone etiology with >95% positive predictive value
3. Cullen + Grey Turner signs = retroperitoneal hemorrhage = necrotizing pancreatitis
4. Hypocalcemia = fat saponification = poor prognostic sign
5. ERCP in gallstone pancreatitis only if cholangitis or persistent CBD obstruction - not routine
6. Enteral > Parenteral nutrition in severe pancreatitis - start within 24-48 hours
7. No prophylactic antibiotics in acute pancreatitis - multiple RCTs showed no benefit
8. Step-up approach for infected necrosis; wait for walled-off necrosis (>4 weeks) before intervening
9. Amylase normal in burned-out chronic pancreatitis - use fecal elastase instead
10. PRSS1 hereditary pancreatitis = 40% lifetime risk of pancreatic cancer - long-term surveillance required

---

• Schwartz's Principles of Surgery, 11th ed., Chapter 33, pp. 1439-1468
• Robbins & Kumar Basic Pathology, Chapter 15, pp. 640-646
• Sleisenger & Fordtran's Gastrointestinal and Liver Disease